Access the full text.
Sign up today, get DeepDyve free for 14 days.
Wollina, Looks, Schneider., Maák (1998)
Disabling morphoea of childhood—beneficial effect of intravenous immunoglobulin therapyClinical and Experimental Dermatology, 23
Nicolas Hunzelmann, K. Kochanek, C. Hager, T. Krieg (1998)
Management of localized scleroderma.Seminars in cutaneous medicine and surgery, 17 1
A. Brasileiro, J. Oliveira, Stéphanie Pinheiro, M. Paiva-Lopes (2016)
Successful treatment of systemic lupus erythematosus with subcutaneous immunoglobulinLupus, 25
Joann Lin, Kevin Wang, Sheryl Kraft, R. Roberts (2009)
Resolution of Warts in Association with Subcutaneous Immunoglobulin in Immune DeficiencyPediatric Dermatology, 26
Vered Molina, M. Blank, Y. Shoenfeld (2005)
Intravenous immunoglobulin and fibrosisClinical Reviews in Allergy & Immunology, 29
Kei Amemiya, Christina Semino-Mora, Rebekah Granger, M. Dalakas (2000)
Downregulation of TGF-beta1 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin.Clinical immunology, 94 2
M. García-Romero, Ronald Laxer, Elena Pope (2016)
Correlation of clinical tools to determine activity of localized scleroderma in paediatric patientsBritish Journal of Dermatology, 174
M. Blank, Y. Levy, H. Amital, Y. Shoenfeld, M. Pines, O. Genina (2002)
The role of intravenous immunoglobulin therapy in mediating skin fibrosis in tight skin mice.Arthritis and rheumatism, 46 6
Xingmu Liu, Tao Huang, Xueling Chen, Meiling Yan, Feiyuan Yu, Huan Gu, Chao He, J. Gu (2016)
Immunoglobulin G promotes skin graft acceptance in an immunologically potent rat modelOncotarget, 7
M. Berger (2014)
Subcutaneous IgG in neurologic diseases.Immunotherapy, 6 1
Morphoea, also known as localized scleroderma, is a disorder characterized by excessive collagen deposition leading to thickening of the dermis and/or subcutaneous tissues. Intravenous IgG therapy has induced improvement in some fibrotic conditions. The primary indication for subcutaneous IgG (SCIG) is in primary immunodeficiency disorders as replacement therapy; however, recently there has been considerable interest in SCIG as an immunomodulatory agent. We report an 11‐year‐old girl with deep morphoea who was successfully treated with SCIG.
Clinical & Experimental Dermatology – Wiley
Published: Jan 1, 2018
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.